Journal article
Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors
The Journal of nuclear medicine (1978), Vol.44(10), pp.1556-1560
2003
PMID: 14530466
Abstract
Because of the presence of cell membrane somatostatin receptors (SSTRs), many neuroendocrine tumors will bind analogs of somatostatin. (90)Y-Dodecanetetraacetic acid-Phe1-Tyr3-octreotide (SMT 487) is an SSTR radiopharmaceutical currently under investigation as a therapeutic option for neuroendocrine tumors. Although there are a variety of methods for evaluating response to a given cancer therapy, an important indicator of success is the impact on the clinical status of the patient. The purpose of this work was to develop a semiquantitative method and assess the clinical effectiveness of (90)Y-SMT 487 therapy in patients with neuroendocrine tumors.
Methods: A scoring system was developed to evaluate clinical response that included the following parameters: weight, health status score (determined by the patient), Karnofsky score, and tumor-related symptoms.
Results: We applied this scoring system to 21 patients who had completed 3 cycles of therapy with (90)Y-SMT 487. Fourteen of the 21 showed a favorable clinical response, whereas 5 were clinically stable after treatment and 2 showed evidence of clinical progression. There was also a significant reduction in the amount of octreotide being used after completion of (90)Y-SMT 487 therapy in the 20 patients who were on this medication.
Conclusion: Using this scoring method, (90)Y-SMT 487 appears effective in improving the clinical status of patients with (111)In-pentetreotide-positive neuroendocrine tumors.
Details
- Title: Subtitle
- Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors
- Creators
- David BUSHNELL - Iowa City Veterans Administration Hospital, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, Iowa, United StatesThomas O'DORISIO - Department of Internal Medicine, Division of Endocrinology, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa, United StatesYusuf MENDA - Department of Radiology, Division of Nuclear Medicine, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa, United StatesThomas CARLISLE - Iowa City Veterans Administration Hospital, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, Iowa, United StatesPamela ZEHR - Department of Internal Medicine, Division of Oncology, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa, United StatesMary CONNOLLY - Novartis Pharmaceuticals, East Hanover, New Jersey, United StatesMark KARWAL - Department of Internal Medicine, Division of Oncology, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa, United StatesSara MILLER - Iowa City Veterans Administration Hospital, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, Iowa, United StatesStan PARKER - Iowa City Veterans Administration Hospital, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City, Iowa, United StatesHakim BOUTERFA - Novartis Pharmaceuticals, East Hanover, New Jersey, United States
- Resource Type
- Journal article
- Publication Details
- The Journal of nuclear medicine (1978), Vol.44(10), pp.1556-1560
- Publisher
- Society of Nuclear Medicine; Reston, VA
- PMID
- 14530466
- ISSN
- 0161-5505
- eISSN
- 1535-5667
- Language
- English
- Date published
- 2003
- Academic Unit
- Radiology; Hematology, Oncology, and Blood & Marrow Transplantation; Radiation Oncology; Endocrinology and Metabolism; Internal Medicine
- Record Identifier
- 9984047877202771
Metrics
32 Record Views